Authors: Zuo T, Wu X, Wen W, Lan P PMID: 34560321 PMCID: PMC8478109 DOI: 10.1016/j.gpb.2021.09.004 Abstract Since the outset of the coronavirus disease 2019 (COVID-19) pandemic, the gut microbiome in COVID-19 has garnered substantial interest, given its significant roles in human health and pathophysiology. Accumulating evidence is unveiling that the gut microbiome is broadly altered [...]

Auhtors: Lee KA, Luong MK, Shaw H, Nathan P, Bataille V, Spector TD Abstract The gut microbiome (GM) has been implicated in a vast number of human pathologies and has become a focus of oncology research over the past 5 years. The normal gut microbiota imparts specific function in host nutrient metabolism, xenobiotic and drug [...]

Authors: Chen Y, Gu S, Chen Y, Lu H, Shi D, Guo J PMID: 33833065 PMCID: PMC8666823 DOI: 10.1136/gutjnl-2021-324090 Abstract We read with great interest the recent article published in Gut in which Yeoh et al demonstrated that gut microbiota composition of recovered patients with COVID-19 remained significantly distinct from uninfected controls. Persisting symptoms, also [...]

Auhtors: Cheng WY, Wu CY, Yu J doi: https://doi.org/10.1136/gutjnl-2020-321153 Abstract The gut microbiota has been implicated in cancer and shown to modulate anticancer drug efficacy. Altered gut microbiota is associated with resistance to chemo drugs or immune checkpoint inhibitors (ICIs), whereas supplementation of distinct bacterial species restores responses to the anticancer drugs. Accumulating evidence has [...]

Auhtors: Zitvogel L, Galluzzi L, Viaud S, Vétizou M, Daillère R, Merad M, Kroemer G PMID: 25609166 PMCID: PMC4690201 DOI: 10.1126/scitranslmed.3010473 Abstract Changes in the interactions among the gut microbiota, intestinal epithelium, and host immune system are associated with many diseases, including cancer. We discuss how environmental factors infuence this cross-talk during oncogenesis and tumor [...]